First-line treatment for symptomatic benign prostatic hyperplasia: is there a particular patient profile for a particular treatment?
- PMID: 16710669
- DOI: 10.1007/s00345-006-0092-0
First-line treatment for symptomatic benign prostatic hyperplasia: is there a particular patient profile for a particular treatment?
Abstract
When the range of treatment options for benign prostatic hyperplasia (BPH) is as broad as the BPH spectrum of symptoms, how should urologists and their patients choose the best initial treatment? Treatment goals should include reducing both lower urinary tract symptoms and relieving associated morbidities, such as urinary retention, persistent gross hematuria, recurrent infections, bladder stones, or renal insufficiency-which are all indications for surgery. However, if one views BPH as a chronic and progressive disease, should a primary goal of BPH management be the prevention of the BPH-associated morbidities? The goal of this paper is to provide a literature update regarding various treatment options in the setting of initial treatment for symptomatic BPH. Novel approaches to BPH management are discussed. In all cases, the risks and benefits of each treatment need to be considered and discussed with the patient; the decision is ultimately up to the patient and his urologist.
Similar articles
-
[Guide dedicated to general practitioner for the management of lower urinary tract symptoms related to benign prostatic hyperplasia].Prog Urol. 2015 Jun;25(7):404-12. doi: 10.1016/j.purol.2015.02.008. Epub 2015 Apr 2. Prog Urol. 2015. PMID: 25841758 French.
-
[Management of the bladder outlet obstruction associated with BPH in patients with special circumstances and/or complications].Prog Urol. 2018 Nov;28(15):868-874. doi: 10.1016/j.purol.2018.08.006. Epub 2018 Sep 13. Prog Urol. 2018. PMID: 30220535 Review. French.
-
Benign prostatic hyperplasia (BPH) management in the primary care setting.Can J Urol. 2012 Oct;19 Suppl 1:10-7. Can J Urol. 2012. PMID: 23089343
-
Benign prostatic hyperplasia evaluation and management by urologists and primary care physicians: practice patterns from the observational BPH registry.J Urol. 2011 Sep;186(3):971-6. doi: 10.1016/j.juro.2011.04.081. Epub 2011 Jul 24. J Urol. 2011. PMID: 21791352
-
Prostatic Artery Embolization (PAE) for Symptomatic Benign Prostatic Hyperplasia (BPH): Part 1, Pathological Background and Clinical Implications.Cardiovasc Intervent Radiol. 2016 Jan;39(1):1-7. doi: 10.1007/s00270-015-1233-x. Epub 2015 Nov 18. Cardiovasc Intervent Radiol. 2016. PMID: 26581418 Review.
Cited by
-
Various treatment options for benign prostatic hyperplasia: A current update.J Midlife Health. 2012 Jan;3(1):10-9. doi: 10.4103/0976-7800.98811. J Midlife Health. 2012. PMID: 22923974 Free PMC article.
-
National-wide data on the treatment of BPH in Korea.Prostate Cancer Prostatic Dis. 2011 Sep;14(3):243-7. doi: 10.1038/pcan.2011.12. Epub 2011 Apr 19. Prostate Cancer Prostatic Dis. 2011. PMID: 21502967 Free PMC article.
-
Clinical efficacy of a loading dose of naftopidil for patients with benign prostate hyperplasia.World J Urol. 2011 Apr;29(2):225-31. doi: 10.1007/s00345-010-0528-4. Epub 2010 Mar 23. World J Urol. 2011. PMID: 20309563 Clinical Trial.
-
Factors influencing nonabsolute indications for surgery in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: analysis using causal bayesian networks.Int Neurourol J. 2014 Dec;18(4):198-205. doi: 10.5213/inj.2014.18.4.198. Epub 2014 Dec 29. Int Neurourol J. 2014. PMID: 25558417 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical